Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
Nine-month period ended 30 September 2016 press release
Tue, 08/11/2016 - 16:45
0 min
2017 Noticia 3.png
Download related document
Select rating
Give Nine-month period ended 30 September 2016 press release 1/5
Give Nine-month period ended 30 September 2016 press release 2/5
Give Nine-month period ended 30 September 2016 press release 3/5
Give Nine-month period ended 30 September 2016 press release 4/5
Give Nine-month period ended 30 September 2016 press release 5/5
No votes yet
Related
Grant of partially reimbursable aid for the assessment of toxicity in...
Madrid - January 28, 2022 Last May, ROVI signed a financing agreement with the Centre for Industrial Technological Development...
1 min
28/01/2022
ROVI receives the positive opinion of the CHMP on Okedi® as a treatment for...
Laboratorios Farmacéuticos Rovi, a pan-European pharmaceutical company specializing and engaging in the research, development, contract...
4 min
17/12/2021
2021 Capital Markets Day presentation
TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION (COMISIÓN NACIONAL DEL MERCADO DE VALORES) Madrid, 16 November 2021 In...
1 min
16/11/2021
See More
Email
Facebook
Twitter
LinkedIn
2017 Noticia 3.png